Research Analysts Set Expectations for BMRN FY2026 Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of BioMarin Pharmaceutical in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst O. Brayer anticipates that the biotechnology company will earn $4.29 per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $90.00 price target on the stock. The consensus estimate for BioMarin Pharmaceutical's current full-year earnings is $3.15 per share.

BMRN has been the topic of a number of other research reports. Bank of America upped their target price on BioMarin Pharmaceutical from $99.00 to $103.00 and gave the company a "buy" rating in a research report on Thursday, February 20th. UBS Group raised their target price on shares of BioMarin Pharmaceutical from $109.00 to $113.00 and gave the stock a "buy" rating in a report on Thursday, February 20th. Piper Sandler upped their price target on shares of BioMarin Pharmaceutical from $122.00 to $126.00 and gave the company an "overweight" rating in a report on Thursday, February 20th. Oppenheimer upgraded BioMarin Pharmaceutical from a "market perform" rating to an "outperform" rating and set a $98.00 price objective for the company in a research note on Monday, February 24th. Finally, The Goldman Sachs Group lowered their target price on BioMarin Pharmaceutical from $124.00 to $104.00 and set a "buy" rating on the stock in a research note on Monday, May 5th. Six investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $93.45.

BioMarin Pharmaceutical Stock Performance

Shares of BMRN traded up $0.60 during trading hours on Tuesday, reaching $57.48. 1,709,451 shares of the company traded hands, compared to its average volume of 1,876,861. The business has a fifty day moving average price of $59.40 and a 200-day moving average price of $64.21. The company has a quick ratio of 2.62, a current ratio of 5.33 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $11.02 billion, a P/E ratio of 26.13, a P/E/G ratio of 0.61 and a beta of 0.19. BioMarin Pharmaceutical has a 12-month low of $52.93 and a 12-month high of $94.85.

Institutional Trading of BioMarin Pharmaceutical

Several institutional investors have recently made changes to their positions in the company. Farther Finance Advisors LLC increased its stake in BioMarin Pharmaceutical by 95.9% during the first quarter. Farther Finance Advisors LLC now owns 431 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 211 shares during the last quarter. Rise Advisors LLC acquired a new stake in shares of BioMarin Pharmaceutical during the 1st quarter worth about $30,000. LRI Investments LLC increased its position in shares of BioMarin Pharmaceutical by 856.9% during the 4th quarter. LRI Investments LLC now owns 488 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 437 shares during the last quarter. SBI Securities Co. Ltd. purchased a new stake in BioMarin Pharmaceutical in the 4th quarter valued at about $36,000. Finally, MassMutual Private Wealth & Trust FSB lifted its position in BioMarin Pharmaceutical by 71.2% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 524 shares of the biotechnology company's stock valued at $37,000 after buying an additional 218 shares during the last quarter. Hedge funds and other institutional investors own 98.71% of the company's stock.

Insider Transactions at BioMarin Pharmaceutical

In related news, CAO Erin Burkhart sold 1,786 shares of the firm's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $59.31, for a total transaction of $105,927.66. Following the completion of the sale, the chief accounting officer now directly owns 14,173 shares in the company, valued at approximately $840,600.63. This trade represents a 11.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 3,354 shares of company stock worth $216,269 in the last quarter. Company insiders own 0.85% of the company's stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.